14-Jan-2026
Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update
PRNewswire (Wed, 12-Nov 4:05 PM ET)
PRNewswire (Wed, 5-Nov 4:05 PM ET)
Talphera Announces the Appointment of Joe Todisco to Board of Directors
PRNewswire (Tue, 21-Oct 8:30 AM ET)
Talphera (TLPH) Jumps 36.61% After $5 Million CorMedix Investment—Phase 3 Study in Focus
Market Chameleon (Mon, 8-Sep 7:00 AM ET)
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
Talphera trades on the NASDAQ stock market under the symbol TLPH.
As of January 14, 2026, TLPH stock price climbed to $1.04 with 113,706 million shares trading.
TLPH has a beta of 0.70, meaning it tends to be less sensitive to market movements. TLPH has a correlation of 0.02 to the broad based SPY ETF.
TLPH has a market cap of $48.47 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that TLPH belongs to (by Net Assets): VXF.
TLPH has outperformed the market in the last year with a return of +80.5%, while the SPY ETF gained +20.0%. However, in the most recent history, TLPH shares have underperformed the stock market with its stock returning -11.1% in the last 3 month period and -3.7% for the last 2 week period, while SPY has returned +4.4% and +0.5%, respectively.
TLPH support price is $.97 and resistance is $1.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TLPH shares will trade within this expected range on the day.